MLICM
ALLO icon

Metropolitan Life Insurance Company (MetLife)’s Allogene Therapeutics ALLO Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,664
Closed -$16.4K – 101
2024
Q1 		$16.4K Buy
3,664
+1,941
+113% +$8.1K ﹤0.01% 1951
2023
Q4 		$5.53K Sell
1,723
-2,618
-60% -$7.42K ﹤0.01% 2281
2023
Q3 		$13.8K Hold
4,341
– – ﹤0.01% 2070
2023
Q2 		$21.6K Hold
4,341
– – ﹤0.01% 1889
2023
Q1 		$21.4K Sell
4,341
-1,378
-24% -$8.84K ﹤0.01% 1854
2022
Q4 		$36K Buy
5,719
+1,286
+29% +$11.9K ﹤0.01% 1678
2022
Q3 		$47.9K Hold
4,433
– – ﹤0.01% 1485
2022
Q2 		$50.5K Hold
4,433
– – ﹤0.01% 1505
2022
Q1 		$40.4K Sell
4,433
-13,481
-75% -$140K ﹤0.01% 1715
2021
Q4 		$267K Sell
17,914
-1,136
-6% -$20K ﹤0.01% 1818
2021
Q3 		$490K Hold
19,050
– – 0.01% 1479
2021
Q2 		$497K Buy
19,050
+3,686
+24% +$105K 0.01% 1531
2021
Q1 		$542K Sell
15,364
-465
-3% -$15.7K 0.01% 1360
2020
Q4 		$400K Buy
15,829
+233
+1% +$7.59K 0.01% 1505
2020
Q3 		$588K Buy
15,596
+711
+5% +$26.8K 0.01% 1100
2020
Q2 		$637K Buy
14,885
+1,856
+14% +$67.1K 0.01% 1039
2020
Q1 		$253K Hold
13,029
– – 0.01% 1455
2019
Q4 		$338K Hold
13,029
– – 0.01% 1563
2019
Q3 		$355K Buy
13,029
+3,040
+30% +$86.6K 0.01% 1511
2019
Q2 		$268K Buy
9,989
+1,227
+14% +$34.2K ﹤0.01% 1694
2019
Q1 		$253K Sell
8,762
-493
-5% -$14.3K ﹤0.01% 1743
2018
Q4 		$249K Buy
+9,255
New +$246K 0.01% 1656

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s ALLO Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Allogene Therapeutics (ALLO) in Q2 2024, closing a stake of 3,664 shares — an estimated $16.4K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in ALLO in Q4 2018 and held it in 22 quarters. The position peaked at $637K in Q2 2020. 174 funds tracked by Wall St. Rank hold ALLO as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Allogene Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 3,664 Allogene Therapeutics shares in Q2 2024, an estimated $16.4K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Allogene Therapeutics in Q4 2018 and held it in 22 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Allogene Therapeutics position peaked at $637K in Q2 2020.
  • 174 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.